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ABSTRACT
Objective: The objective of this study was to evaluate
general practitioners’ (GPs) perceptions regarding
access to medicines in New Zealand.
Design: Qualitative.
Setting: Primary care.
Participants: GPs.
Main outcome measures: GPs’ views and
perceptions.
Results: GPs were of the view that the current range of
medicines available in New Zealand was reasonable;
however, it was acknowledged that there were some
drugs that patients were missing out on. When
considering the range of subsidised medicines
available in New Zealand, some GPs felt that there had
been an improvement over recent years. It was
highlighted that unexpected funding changes could
create ﬁnancial barriers for some patients and that
administrative procedures and other complexities
created barriers in receiving a subsidy for restricted
medicines. GPs also reported problems with the
availability and sole supply of certain medicines and
claimed that switching from a branded medicine to its
generic counterpart could be disruptive for patients.
Conclusions: The research concluded that although
there were some issues with the availability of certain
drugs, most GPs were satisﬁed with the broader
access to medicines situation in New Zealand. This
view is to contrary to the situation presented by the
pharmaceutical industry. The issues around sole
supply, the use of generic medicines and the
administrative barriers regarding funding of medicines
could be improved with better systems. The current
work provides a solid account of what GPs see as the
advantages and disadvantages of the current system
and how they balance these demands in practice.
INTRODUCTION
One of the aims of New Zealand’s medicines
policy is to ensure that New Zealanders have
access to affordable medicines.
1 New Zealand
has been successful in containing pharma-
ceutical costs, primarily via the policies of the
Pharmaceutical Management Agency of
New Zealand (PHARMAC).
2 PHARMAC is
the New Zealand government agency that
decides which medicines are subsidised. It
was created in 1993 to ensure that New
Zealanders get the best possible health
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ARTICLE SUMMARY
Article focus
- To evaluate GPs’ perceptions regarding access to
medicines in New Zealand.
- To identify GPs’ views and perceptions regarding
the role of PHARMAC within the New Zealand
healthcare system.
Key messages
- GPs were of the view that the current range of
medicines available in New Zealand was reason-
able; however, it was acknowledged that
there were some drugs that patients were
missing out on.
- When considering the range of subsidised
medicines available in New Zealand, some GPs
felt that there had been an improvement over
recent years.
- It was highlighted that unexpected funding
changes could create ﬁnancial barriers for
some patients and that administrative proce-
dures and other complexities created barriers in
receiving a subsidy for restricted medicines.
Strengths and limitations of this study
- This is the ﬁrst independent objective study
covering GPs’ perceptions regarding access to
medicines issues in New Zealand.
- Findings from this study will form an essential
component of any future research, which reviews
New Zealand’s current medicines policy.
- It will also help in developing strategies to better
inform patients’ access to medicines, with GPs
being a large group of health professionals likely
to positively affect patient knowledge and views.
- All GPs were working in a large metropolitan city
in New Zealanddit is not known whether their
views and experiences differ from colleagues
working and living in small towns and rural
locales.
- Also, only 19 of 150 contacted were interested in
participating so this could be another source of
bias in the study.
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Open Access Researchoutcomes from money the government spends on
medicines.
3 PHARMAC manages drug costs by applying
pharmacoeconomic techniques when selecting medi-
cines and by promoting the use of generic medicines.
45
It uses a capped national medicines budget, along with
a variety of contractual arrangements with pharmaceu-
tical companies that enables a company’s medicine to be
listed onto the Pharmaceutical Schedule and therefore
enables access to subsidies for consumers. These
contractual arrangements include rebates on list prices
from PHARMAC, tendering for off-patent drugs and
bundle agreements where PHARMAC may list expensive
new drugs in its Pharmaceutical Schedule
6 in return for
the manufacturer discounting the price of other prod-
ucts it supplies.
7 Most off-patent drugs listed in New
Zealand’s Pharmaceutical Schedule
6 are supplied from
one supplier under contract to PHARMAC (sole supply)
and large price discounts are provided in exchange for
exclusivity.
7
In community settings, only drugs on the Pharma-
ceutical Schedule receive government subsidy.
7 The
government subsidy means that consumers who are New
Zealand citizens or who have Permanent Residence
make a co-payment (NZ$3; US$2.20) per prescription
item) for each medicine listed in the Schedule. If the
subsidy-level PHARMAC has set for a particular medi-
cines is less than the price charged by the drug company,
then patients pay an additional fee, known as ‘manu-
facturers surcharge’. For the medicines that are not
listed on the Schedule, consumers are required to pay
the full price.
With an annual drug budget expenditure for subsi-
dised medicines used in the community setting of NZ
$599 million in 2007,
8 over 78% of all consumed medi-
cations are publicly funded in New Zealand. Although
PHARMAC has played an important role in containing
the pharmaceutical budget in New Zealand, in 2009,
medicines expenditure was recorded as $694 million
a year and is expected to increase to NZ$734 million by
2012.
9e11 Healthcare expenditure is a key concern for
many countries and countries amend and form their
policies on the basis of ongoing empirical research.
General practitioners (GPs) form a vital part in this
research process because they are key stakeholders in the
access to medicines process. GPs are the main
prescribers in New Zealand and prescribe over 44
million prescriptions annually.
12 They inﬂuence the
‘demand side’ of cost, and knowing what they think
about ‘access to medicines’ is important when exploring
the impact of a country’s medicines policy. Although
very little independent research is available on GP views
on access to medicines in New Zealand,
13 some research
has been conducted by the pharmaceutical industry.
One industry study of a sample of 528 GPs in New
Zealand revealed GPs’ dissatisfaction over the current
system, and it was observed that a large majority (75%)
of GPs supported a general review of PHARMAC.
14 It was
also reported that GPs felt that PHARMAC was ‘too
budget oriented’ rather than patient focused, its deci-
sion making ‘lacks transparency’ and New Zealand’s
access to medicines ‘lags behind other comparable
countries’. Furthermore, the study also found that 71%
of clinicians rated New Zealanders’ access to medicines
as ‘poor’ when compared with Australia.
14 PHARMAC
has undertaken its own research
15 exploring health
professionals’ perceptions about how it functions
(n¼23), but only investigated PHARMAC’s operational
abilities and did not assess issues of access, availability
and affordability of medicines.
13 16
While the New Zealand government promotes afford-
able medicines,
3 4 the media has portrayed New
Zealanders as having problems regarding accessing
medicines.
17 Furthermore, it has been argued that
‘newer’ and ‘more effective’ medicines available abroad,
such as risedronate, atomoxetine, galantamine and
montelukast, are not available in New Zealand.
17e19
Hence in this context, the current study was under-
taken. The key aims of the study were to evaluate GPs’
perceptions regarding access to medicines in New
Zealand and to identify GPs’ views and perceptions
regarding the role of PHARMAC within the New
Zealand healthcare system.
METHODS
A qualitative approach was adopted for the study, which
was undertaken in November 2008 to January 2009 in
Auckland, New Zealand. Auckland is New Zealand’s
largest city, with approximately 1.25 million people
residing in the greater Auckland area (about one-third
of the population of the whole country).
20 The Auckland
region is covered by three District Health Boards
(DHBs), of which there are a total of 20 in New Zealand.
DHBs are responsible for providing, or funding the
provision of, health and disability services in their
district.
21 A list of GPs practicing within the greater
Auckland region was obtained from the Department of
General Practice and Primary Health Care at the
University of Auckland. GPs were stratiﬁed according to
the DHB in which they were located (n¼360 for Auck-
land DHB; n¼393 for Counties Manukau DHB; n¼482
for Waitemata DHB). Fifty GPs were randomly selected
from each DHB list and were sent information regarding
the study (n¼150 in total). This included a participant
information sheet, which provided an overview of the
research study and processes, and a research consent
form (with a freepost envelope) that GPs could complete
and return to the research team to indicate their interest
in participating.
A series of face-to-face, semi-structured interviews was
undertaken. Questions were developed following a
review of the relevant literature and to explore GPs’
perceptions regarding access to medicines in New
Zealand and views and perceptions of the role of
PHARMAC in relation to medicines access in New
Zealand (a detailed list of the questions is attached in
table 1). Demographic information, including age,
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General practitioners’ perceptions regarding access to medicinesgender, practice type and length of time practicing, was
also recorded for each GP at the time of the interview.
The interview guide was piloted with two health profes-
sionals prior to the ﬁeldwork commencing and further
reviewed (and amended) following the completion of
the ﬁrst two interviews. Interviews took place at the GP’s
workplace. Seventeen interviews were conducted, at
which stage data saturation was reached. Most were
around 35 min in duration (range: 23e41 min), and all
were audiotaped. GPs who took part in the study were
offered a $50 book voucher in recognition of their
contribution to the research.
All interviews were transcribed verbatim with the full
transcripts utilised in the subsequent analysis process.
Analysis of the data was undertaken by the research team
via a staged process. In the ﬁrst instance, transcripts were
read and notes were taken regarding key themes and
issues. Following this, a basic coding framework was
developed, and interview data were coded, with the
assistance of the NVIVO software programme. Lastly,
a series of group analysis sessions involving the senior
members of the research team were conducted, whereby
further reﬁnement of the themes was undertaken. Each
‘quote’ from within each theme was read by a member of
the research team and a brief interpretation of the quote
written on a ‘post-it’ note. These were then placed on
a board and moved around into subthemes.
Ethical approval for the study was gained from the
University of Auckland Human Participants’ Ethics
Committee (Reference: 2008/445).
RESULTS
A total of 19 GPs returned a research consent form and
17 of those were interviewed. Over half the participants
(n¼10) had been practicing as a GP for more than
20 years, and 13 were men. GPs were recruited from each
of the DHBs, although the majority were based within
Counties Manukau DHB (n¼10). An overview of the
demographic characteristics of the sample is provided in
table 2. Key ﬁndings from the research are presented
below.
General perceptions of access to medicine in New Zealand
When considering the range of (subsidised) medicines
available in New Zealand, some GPs felt that there had
been an improvement over recent years and thatdfor
the most partdsufﬁcient drugs were subsidised and able
to meet the needs of most patients.
Table 1 List of questions utilised in interviews with general practitioners (GPs)
Domain 1eGPs’ perceptions regarding access to medicines and high cost drugs in New Zealand
A What is your understanding of the ‘access to medicines’ in New Zealand?
B In your opinion what is the current state of access to medicines and high cost drugs in New Zealand and why?
C If and how has this access changed in the past few years?
D What role do GPs play in determining the access to medicines in New Zealand?
E How do you compare the access to medicines and high cost drugs in New Zealand with that of other
developed countries?
F The current notion by drug industries is that access to medicines in New Zealand is inadequate.
What is your opinion?
G Do you believe high costing medicines are readily accessible in New Zealand? Are there any examples
you would like to mention?
H Are there examples of medicines you would like to see being available in New Zealand?
Domain 2eViews and perceptions regarding the role of Pharmac (Pharmaceutical Management Agency of New Zealand) to
access of medicines in New Zealand.
A What is your understanding of the role of Pharmac in New Zealand healthcare system?
B Do you think New Zealand needs an agency like Pharmac? Why?
C Pharmac has been under immense public scrutiny. Is it justiﬁed?
D How successful has Pharmac been in achieving its aims?
E How does Pharmac inﬂuence the access to medicines for New Zealanders?
F How do you ﬁnd the decision making process undertaken by Pharmac?
G Does Pharmac have sufﬁcient representation from various health professionals and consumer groups?
H What are your views on communication between Pharmac and GPs?
Table 2 Overview of general practitioner (GP) sample
N
Number of
participants (GPs)
District Health Board
Auckland 5
Counties Manukau 10
Waitemata 2
Gender
Male 13
Female 4
Age of participants (yrs)
<40 4
40e60 10
60+ 3
Experience (yrs)
<10 3
10e20 4
20+ 10
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General practitioners’ perceptions regarding access to medicines95% I’m happy with what we have got. There are a small
number of things which I would like more direct access to as
a general practitioner. But I’m not aware of, and that may just be
ignorance, of any major drugs or drug classes that we have zero
access to. Most of the things that I’m aware of that are of any
genuine value we have at least some access to. [GP3]
Some comments were made, however, about the range
being fairly basic or limiteddparticularly in relation to
there being few options available, in terms of the
number of brands subsidised within certain classes of
drugs. This included medicines such as statins and ACE
inhibitors. While some GPs were accepting of this,
particularly in light of the country’s limited drug budget,
other reported that it could become an issue in certain
circumstances (eg, where a speciﬁc medication was not
effective for a patient):
I would say that I have to struggle sometimes if one is not
working. What can I do more to get it? What else can I try? So
there are very limited options? [GP1]
One GP noted that while they felt the current range of
medicines available in New Zealand was ‘reasonable’,
they highlighted that it was likely there were some drugs
that patients were missing out on. However, they also
indicated that it was not always possible to know what
these were:
For most GPs I think it is 30 drugs that cover 90% of your
patients or something. So you kind of concentrate on those and
the other ones you worry about but you don’t actually worry about
what you can’t prescribe. [GP7]
GPs were asked their views on the pharmaceutical
industry’s opinion that access to medicines is poor.
There was limited agreement with this claim. Some GPs
were dismissive of it, citing the self-serving nature of the
statement and the fact that the pharmaceutical industry
would have much to gain from promoting such
a scenario:
Of course they would [say that]. They’ve got a vested interest . I
wouldn’t listen to them [laughter].. A company has only got
proﬁt in mind, yeah. .I mean they’re playing a devil’s advocate
to PHARMAC so obviously they need to be there and they need to,
they need to advertise their products to PHARMAC, but you
know, they’re only there for proﬁt. [GP9]
Others reported that, while it may be an issue in rela-
tion to some medicines, it was not a widespread occur-
rence. One GP noted that, due to the restrictive nature of
New Zealand’s pharmaceutical market, drug companies
could see limited opportunities for marketing and
reimbursement for their products and were subsequently
withdrawing. While this was viewed as a potential
problem, it was also seen to be inevitable, given the small
size of the country (and associated drug budget).
Affordability of medicines
Patients in New Zealand are often required to pay a co-
payment fee which ranges from NZ$3 to NZ$15 per item
for subsidised medicines. However, from 1 September
2008
22 (shortly before the research was conducted), the
eligibility criteria for the lower co-payment of NZ$3 was
expanded. In some cases, however, patients still had to
pay up to a maximum pharmaceutical co-payment of NZ
$15 per item.
22 This is when the patients are not
enrolled in a Primary Health Organisation
i (PHO), if the
prescription is from a private specialist (who is not part
of the publicly funded system) or the patient does not
have a Community Services Card or a Prescription
Subsidy Card (PSC).
ii
It was acknowledged by GPs who took part in the study
that the widening of the NZ$3 co-payment had improved
access to medicines for patients, given the lower fee
structure. In particular, GPs felt that the NZ$3 per item
fee was at a level that most people would be able to
afford, with some indicating that some level of fee was
appropriate:
I think that by and large we have in New Zealand a good number
of subsidised medications to use. So, the subsidy level such that
the patients pay 3NZ$ I think is appropriate. I think that’s, you
know, I think sometimes if a thing’s made completely free it’s
wasted. Its value is degraded. So, and yet that’s a ﬁne line
between that and preventing access. [GP12]
Some GPs, however, were of the view that cost
remained a barrier to accessing medicines for some
people. This included people not registered with a PHO,
those on limited incomes (including teenagers and the
elderly) and patients with an extensive medicine regime:
I think the people who are on a large number of medications and
I’ve got some here on 12 or 13 different pills... Most of those
people don’t work, they are on a beneﬁt so they are actually a little
bit limited. Once they pay for 30 items [sic- 20 items] then they
are ﬁne but that is still $100 so for them, it is quite a cost or can
become a cost. [GP7]
For some, the PHO enrolment system was seen as
somewhat arbitrary, with one GP commenting that it was
a ‘ridiculous’ system, as ‘essentially everyone is either
registered [with a PHO] or should be’. Other GPs,
however, highlighted that the system encouraged
patients to access their healthcare from one provider
only, which was likely to have greater beneﬁts than
visiting a number of different general practices.
Comments were also made regarding the complexity of
the system, resulting in confusion for some patients:
iPrimary Health Organisations in New Zealand are health providers
that are funded on a capitation basis by the New Zealand Government
via District Health Boards.
iiCommunity services card are issued for the patients with lower
socioeconomic status, while the PSC is for a family unit that has
received 20 initial dispensing of single supplies of subsidised
pharmaceuticals in the year commencing 1 February to 31 January.
People entitled for PSC are entitled for a reduce co-payment charges
of NZ$2 per prescription item 22. DHBNZ. Pharmacy Procedures
Manual, 2010.
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General practitioners’ perceptions regarding access to medicinesObviously encouraging patients to see their own doctor is a good
thing, but there seems to be some inconsistencies between $3 and
$15, whether they’re funded or non-funded, enrolled or un-
enrolled patient. You know, there’s the question of waiting for
three months before they become funded and enrolled and it
becomes so, such confusion to patients. [GP8]
Affordability of non-subsidised medicines was
discussed by GPs during interviews, with comments
made about these being very expensive and only being
accessible to the ‘rich’. Particularly for those GPs
working in lower socioeconomic areas, the cost to the
patient was a key consideration when deciding which
medicines to prescribe:
I work in South Auckland at the moment and I’ll be choosing
subsidised medications and I know that, in the large majority, if
it is non-subsidised medication it will be a signiﬁcant ﬁnancial
strain for people. [GP4]
Cost to a patient has a major inﬂuence on me. And in that I
routinely prescribe generics and I tend to pre-warn people if
something is going to cost an additional, or is not subsidised. Or
sometimes ring the chemist to see what’s cheaper and what it will
cost. [GP3]
Changes regarding medicines subsidy and access to
medicines
GPs talked about amendments in drug subsidy, which
could affect patients. This meant that prices sometimes
ﬂuctuated, with reports that the changing costs some-
times angered patients. As evident in the interview
extract below, unexpected funding changes could create
ﬁnancial barriers for some patients and ultimately result
in medicines not being accessed:
Those are snags that all of a sudden the rules change and you
don’t know about it and you have written a prescription for
a child to have a medicine which normally would have been
funded fully, no price whatsoever e and all of a sudden there is
a change and now the parent goes to go and pick up [name of
medicine] and now there is a partial charge to it. .and the
pharmacy calls me up in the middle of my next consultation and
the parents have gone away because they couldn’t afford the $7 or
whatever the part charge was. [GP6]
Another GP reported that keeping up to date with
the subsidy changes was challenging and also some-
times resulted in medication regimes needing to be
amended:
I suppose my main comment would be about the things changing
which cause us major problems having to rethink a medication
regime that me may have just got really ﬁne tuned. That’s the major
problem. The other major thing I suppose is keeping up with the
continuous changes of what is subsidised and what isn’t. [GP4]
GPs reported that, for patients, the system was also
confusing, particularly with regard to what medicines
were funded and when (eg, if accessed ‘out of hours’
higher charges are incurred). One research participant
noted that informing patients about these issues
sometimes dominated patienteGP discussions, at the
expense of other important health-related issues.
Administrative issues
Despite a general level of support expressed by GPs
regarding the range and accessibility of subsidised
medicines, the research identiﬁed perceptions of the
New Zealand system as being somewhat ‘complex’. GPs
spoke about this being an issue both for themselves as
health professionalsdas well as for patients. Some GPs
claimed that they did not always understand all the codes
utilised (including ‘section 29’
iii) and that the eligibility
criteria for subsidies were inconsistent. Research partic-
ipants also spoke about the system being based on
controlling costs rather than patient care, with examples
provided of drugs thatdat the time of the
researchdwere unable to be prescribed by GPs (eg,
initially only specialist could prescribe isotretinoin,
however, later on GPs were allowed to prescribe
with subsidy from 1 March 2009).
23 With no apparent
clinically-related reasons for this, it was therefore
assumed that these were budget-related decisions.
GPs spoke about having to undertake ‘a lot of paper-
work’ in order to receive a subsidy for medicines which
are not listed for subsidy on the Pharmaceutical
Schedule. This mostly related to processes for medicines
requiring Special Authority. ‘Special Authority’ means
that the medicine is only eligible for subsidy for
a particular person if an application meeting the criteria
speciﬁed in the PHARMAC Schedule has been
approved.
20 Once approved, the prescriber is provided
with a Special Authority number, which can provide
access to subsidy for a speciﬁed medicine. Applications
can be made electronically via the internet, although
a paper-based system was also still in operation at the
time of the research. It should be noted that one
research participant, at least, was still using the old
system, and another reported that they did not have
access to the electronic system at their practice. This
process was felt to be time consuming, and add to an
already heavy workload, and burdensome:
We have a lot of medication in here, but then there’s a lot of
loopholes that we have to jump through to get those medications,
you know, just like a lot of those special authority regulated
medications. it creates so much more work for us before we can
actually get the medication and so I guess a lot of those special
authority medication if they can be available without special
authority that would be quite good. [GP8]
Having to reapply for Special Authority was also raised
as an issue, particularly where medication was required
for a long-term condition. Other comments made by
research participants included the fact that ‘too many’
medicines still required Special Authority approval (one
GP noted that many of these were ‘freely available’
overseas) and that the system and policy remained
iiiSection 29 is law that permits an unregistered medicine in New
Zealand to be procured and supplied to patients.
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General practitioners’ perceptions regarding access to medicinescomplex. Some GPs stated a desire for GPs to gain
greater control of Special Authority medicinesdin terms
of being able to prescribe those that had been around
for a longer period. It was also suggested that barriers in
accessing Special Authority medicines should be
removed for GPs who have been vocationally trained or
who have special prescriber designation.
Despite some dissatisfaction with the system, it was
acknowledged that the number of medicines requiring
Special Authority had reduced over time. In addition, it
was reported that the introduction of an electronic
process for making applications had improved things
considerably. There were also comments made about
the protection that limited/restricted access affords GPs,
in cases where patients are requesting a particular
medicine that they do not feel comfortable prescribing
(eg, methylphenidate).
It was also acknowledged by GPs that a system that
placed some restrictions on access to medicines was
appropriatedand that patients should not have open
access to any medicine they requested nor that GPs
should have the right to prescribe whatever they wanted,
unrestricted. Findings from the research suggest that
GPs considered the limitations appropriate, due to the
need to improve rational use of medicines, to control
costs, as well as safeguard against potential harm to
patients:
I think that if their [special authority restrictions] aim is to
reduce waste, I think sometimes an application and then a reap-
plication process is sensible, because many times I see in primary
care a person’s started on an agent and it’s just continued
without thought and conscious review of whether that agent’s still
needed and that can be an instance that causes harm [GP12]
Well of course originally everything was totally free, and there
was a much small, there was much smaller number of drugs
provided back in the old days. And there really were no cost
incentives for patients to comply.. I think it’s changed, it’s
a little bit more rational now in terms of that .I think, there’s
probably for some people there probably is a price barrier whereas
thirty years ago there were not, there was not. But again as I said
I’m not unhappy having that signal there. [GP11]
Sole supply
As part of their cost containment system, PHARMAC
issues requests for proposals from pharmaceutical
companies for the sole supply of speciﬁc medicines, with
the contract awarded to the cheapest supplier.
9 While
the ﬁnancial savings are a clear beneﬁt of the sole supply
system, negatives such as the risk of drug shortages due
to a reliance on only one supplier were mentioned by
GPs:
I think the sole supply thing from time to time has found to be
wonky..I mean as soon as you have got sole supply you are
heading for disaster because it is only one shipment away from
either don’t have any or something goes wrong like what
happened with adrenaline..It seems like a crazy business model
which has repeatedly failed in the past and I can’t see why it is
not going to fail in the future. [GP7]
As highlighted above, historical examples such as
an epinephrine shortage in 2007 and other incidents
such as problems with the supply of the ﬂu vaccine were
cited.
Brand switching/generic medicines
In New Zealand, PHARMAC manages the drug budget
by negotiating with drug companies; competition
between suppliers is also encouraged.
6 Switches from
a branded medicine to a generic version (and between
different brands as a means of cost-saving) are
commonplace.
20 At the time of writing, the Pharma-
ceutical Schedule listed 2000 funded medicines, the
majority of which are generics.
20
GPs reported that the switching from a branded
medicine to its generic counterpart could be disruptive
for patients. For example, issues such as the medicine
being a different colour, or of a different name, could
upset patients who sometimes needed added reassur-
ance from their GP that the newly introduced medica-
tion was essentially the same medicine and would do the
same job. It was also commented that patients sometimes
viewed the replacement medicine as being inferior:
Each time the colour or something is changed, it is tough. Just
recently I had a tough time explaining to a patient that it was the
same medicine at the same strength and it just had a different
colour. He still isn’t convinced. I don’t know what to do. [GP1]
Changes could be particularly disruptive for patients
who were taking a wide range of medicines and
expressed frustration that GPs as health professionals
working at the ‘frontline’ were not consulted before
changes were introduced:
Every so often there is a major problem with the change of generic
formulation. . Those sorts of changes occur without sort of any
face talk from us and they are to do with widely prescribed
medications ... I think if something is broadly prescribed then
widespread changes are inadvisable without, you know, asking
GPs’ opinion about it because we often have the front line
appreciation of how differences in medicines do affect patients
differently. [GP4]
Another GP highlighted that a recent switch from
a branded paracetamol to a generic formulation had
created difﬁculties for some patients and that reactions
to a replacement for Ritalin had varied across different
individuals:
I also don’t agree with the information written in it saying that
generics are as good as the original drugs. A lot of cases that has
been proved not to be the case either in presentation, formulation.
I mean the example would be the cheap Panadol
TM [sic-para-
cetamol] they have got which dissolves before people can swallow.
The problem with clogging of Salamol
TM [salbutamol] pills [sic -
inhaler]. The change in the effectiveness of Ritalin
TM for
example. I think it is about 40% of people reacted quite differ-
ently to it and to say that new drug is as good is absolute rubbish.
So I think that’s why I refuse to hand out PHARMAC’s stuff.
I just won’t do it. [GP7]
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General practitioners’ perceptions regarding access to medicinesDISCUSSION
This study set out to explore the views of GPs in relation
to access to medicines in New Zealand. GPs were
generally satisﬁed with the range of medicines available
and noted that there had been a recent improvement
but raised some issues in relation to speciﬁc drug avail-
ability and a narrow range within some classes. There
were concerns about ﬁnancial barriers for some patients.
In some respects, the ﬁndings from our research seem to
be at odds with those in relation to pharmaceutical
industry research on GP views, in which GPs seem to be
generally not satisﬁed with the range of medicines
available, in terms of meeting the needs of their
patients
13 and also the industry point of viewpoint which
claims issues with access.
17
While in this study the range of subsided prescribed
medicines available was broadly supported, GPs high-
lighted that the cost of prescriptions could act as
a barrier for some patients. This is similar to another
New Zealand study
24 which stated that out of a total of
18320 respondents, 6.4% reported that they had
deferred collecting a prescription at least once during
the preceding 12 months because they could not afford
the cost of collecting the prescription. Younger adults
aged 15e24 years, females, smokers, M aori and Paciﬁc
patients, and those with the lowest income status were
more likely not to obtain or buy prescription drugs
because of cost barriers.
24 However, it is important to
note that since September 2008, the co-payment for
prescribed medicines have been decreased from NZ$15
to NZ$3 for many people. It was acknowledged by the
GPs in this study that the widening of the NZ$3 co-
payment had improved access to medicines for patients,
given the affordability of the lower fee structure.
Sole supply and the perceived risk of drug shortages
were raised as an issue by GPs in this research. Other
problems with sole supply have previously been
reported, including the poor quality of slow release
morphine and a brand of felodipine with questionable
pharmacokinetics and bioequivalence.
25 In addition, the
ﬂu vaccine chosen for sole supply in 2005 was under-
strength in one of the three component ﬂu strains, and
another company had to step in to supply the vaccine.
25
However, PHARMAC reiterates that reference pricing
and sole supply occurs only where it is clear that a loss of
choice between one equivalent brand of drug and
another is not considered critical.
26 It has been
suggested that it may be possible to manage some of the
problems around sole supply through contingency and
indemnity clauses in tendering contracts.
7
The GPs in this study also discussed many adminis-
trative barriers regarding accessing medicines, including
Special Authority, restrictions on prescribing certain
medicines and a fair amount of paper work. However,
since the research was conducted, many of these
administrative issues may have been solved by instituting
a system of electronic Special Authority application.
27 28
In addition, while issues were evident regarding Special
Authority applications, it should be noted that only
a small proportion of people are taking medicines that
require a Special Authority in order to access the subsidy
for a speciﬁed medicine (eg, it was found that <1% of
patients require statins through Special Authority).
29 30
Furthermore, many restrictions to medicines have clin-
ical dimensions and are not simply in place because of
issues related to cost containment. For example, prior to
March 2009, isotretinoin (Roaccutane) was only avail-
able on ‘specialist only prescription medicines’.
31
Recently, the specialist prescribing requirement was
removed; however, the decision has been criticised by
the New Zealand Dermatological Society stating that
isotretinoin is prone to misuse.
32 Moreover, these
restrictions are not something which are speciﬁc to the
New Zealand scenario and are quite common in
Canada,
33 Australia
34 35 and the UK.
36 Nevertheless,
there remain issues around sole supply and administra-
tive barriers regarding funding of medicines, which
could be perhaps improved with better systems.
Concerns were also raised by research participants
regarding brand switching, and with respect to generics,
which were viewed by some GPs as being of lower quality.
Similar ﬁndings were observed in a New Zealand report,
which evaluated stakeholders’ views regarding generic
substitution. The report found that although PHARMAC
and pharmacists agreed with generic substitution,
physicians opposed the proposal for voluntary generic
substitution citing concerns, which included reduced
patient compliance, patient confusion and quality and
bioavailability.
37 However, on the one hand, research
indicates that most generic medicines provide the same
quality, safety and efﬁcacy as the original brand name
product and are typically 20%e90% less expensive than
the brand name original.
38 While generic medicines are
associated with large cost reductions, ﬁndings from
a study evaluating consumer perceptions in Auckland
suggest that older patients and patients with chronic
conditions needed more information about generic
medicines. Less than half of survey participants viewed
generic medicines ‘to be as safe, effective and equivalent
in quality’ than branded medication.
39 In addition, in
a PHARMAC discussion, it was noted while the term
‘generic’ is well understood by PHARMAC, the public
may simply regard them as ‘cheap’.
40 Moreover, it has
been shown that the physician views can strongly inﬂu-
ence those of their patients.
39 40 With Medicines New
Zealand, New Zealand’s medicines policy, promoting the
use of generic drugs and stating that consideration must
be given to ‘cost-effective treatment options’,
1 it is vital
that apart from assuring the quality of generic medi-
cines, programmes that educate prescribers and patient
about brand switching are required.
The above mentioned is a key account of what GPs see
as the advantages and disadvantages of the current
system and how they balance these demands in practice.
Though there are matters related to affordability of
medicines and the decisions doctors face clinically and
Babar Z-U-D, Grover P, Butler R, et al. BMJ Open 2012;2:e000518. doi:10.1136/bmjopen-2011-000518 7
General practitioners’ perceptions regarding access to medicinesadministratively, these issues are not speciﬁc to New
Zealand. Doctors and general physicians all over the
world face similar issues related to cost containment and
the clinical prescribing. For example, in a study of GPs in
the UK, it was found that almost all GPs believed that
cost should be taken into account; however, conﬂict has
been observed regarding policy related to cost contain-
ment and GPs’ resistance to cost-cutting.
41 In Singapore,
costs related to differential subsidies in the consultation
fees and the availability of medicines at public polyclinics
and GP clinics were key factors in inﬂuencing the family
physicians’ asthma drug treatment decisions.
35 Also, in
a Canadian study, it was reported that most physicians
mentioned that drug reimbursement guidelines
complicated their prescribing process and can require
lengthy interpretation and advocacy for patients who
require medication that is subject to reimbursement
restrictions.
42
Limitations of the study
All GPs were working in a large metropolitan city in
New Zealanddit is not known whether their views and
experiences differ from colleagues working and living in
small towns and rural locales. Also, only 19 of 150
initially contacted were interested in participating so this
could be another source of bias in the study.
CONCLUSIONS
While GPs in this study had some issues with the avail-
ability of certain drugs, they were generally satisﬁed with
the access to medicines in New Zealand in primary care.
The issues around sole supply, the use of generic medi-
cines and the administrative barriers regarding funding
of medicines could be improved with better systems. The
work provides a solid account of what GPs see as the
advantages and disadvantages of the current system and
how they balance these demands in practice. Findings
from this study will form an essential component of any
future research, which reviews New Zealand’s current
medicines policy.
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